Global orphan drug market drive by high profitability rate

135 views

Published on

Global Orphan Drug Market Report Highlights:

Orphan Designated Drugs in Clinical Phase: 600
Marketed Orphan Designated Drugs: 281
Highest Number of Drugs in Phase-2 Trial: 231
US Dominates Clinical Trial Process: 350 in Pipeline (Research till Registration)
Indication for Clinical Trials for Orphan Drug: More than 30% for Cancer Treatment
Share of Biological in Orphan Drug: More than 60%
Major Market: US (Sales > US$ 40 Billion)
Why Shift to Orphan Drugs
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across US, Europe & Asia
Market Specific Reimbursement Policy for US, Europe & Asia
Regulatory Framework for US, Europe & Asia
Orphan Drug Pipeline by Phase, Orphan Designated Indication & Country

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
135
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

×